AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01367028 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Trastuzumab, Docetaxel
Description: 6 cycles - Day1 (Day22 = Day1): Trastuzumab: 8 mg/kg loading dose (1st cycle) i.v.; 6 mg/kg maintenance dose in subsequent cycles i.v.~Docetaxel: 100 mg/m2 by 60 min i.v. infusion
Study NCT01367028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab, Docetaxel, Bevacizumab
Description: 6 cycles - Day1 (Day22 = Day1): Trastuzumab: 8 mg/kg loading dose (1st cycle) i.v.; 6 mg/kg maintenance dose in subsequent cycles i.v.~Docetaxel: 100 mg/m2 by 60 min i.v. infusion Bevacizumab 15 mg/kg
Study NCT01367028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab+Docetaxel+NPLD
Description: 6 cycles - Day1 (Day22=Day1): Trastuzumab: 8 mg/kg loading dose (1st cycle) i.v.; 6 mg/kg maintenance dose in subsequent cycles i.v.~Docetaxel: 75 mg/m2 by 60 min IV infusion NPLD 50 mg/m2 by 60 min i.v. infusion
Study NCT01367028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab+Docetaxel+NPLD+Bevacizumab
Description: 6 cycles - Day1 (Day22= Day1): Trastuzumab: 8 mg/kg loading dose (1st cycle) i.v.; 6 mg/kg maintenance dose in subsequent cycles i.v.~Docetaxel: 75 mg/m2 by 60 min i.v. infusion NPLD: 50 mg/m2 by 60 min i.v. infusion; Bevacizumab 15 mg/kg
Study NCT01100554 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sleep endoscopy
Description: Conscious sedation will be done under intravenous propofol infusion. The sedative level would be monitored and adjusted accord to the Bispectral Index monitor. After the adequate sedative level is achieved, a bronchoscopy (Olympus, BF) was inserted from the right nostril. The velopharynx, oropharynx, larynx, and hypopharynx obstructions were evaluated.
Study NCT03521726 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Amoxicillin
Description: Twenty patients receive Intraluminal Amoxicillin eradication for H. pylori.
Study NCT03521726 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Rabeprazole, Amoxicillin
Description: Patients fail to achieve intraluminal eradication of H. pylori will be assigned to the oral antibiotic rescue therapies with high dose dual therapy (Rabeprazole, Amoxicillin) for 14 days.
Study NCT00834106 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine
Description: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine injection at Day 1, Month 2, and Month 6.
Study NCT00834106 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: placebo (unspecified)
Description: Aluminum-containing Vaccine placebo injection at Day 1, Month 2, and Month 6.
Study NCT03659448 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SGM-101
Description: A fluorochrome-labeled anti-carcinoembryonic antigen (CEA) monoclonal antibody intraoperative imaging agent.
Study NCT00480701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [123I]-IBVM
Description: Subjects will be asked to undergo an injection of 123-I IBVM followed by up to three approximately thirty minute SPECT scans during the next 24 hours.
Study NCT04679181 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedecine
Description: telemedical consultation
Study NCT03022201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-9701
Description: Following 2-week screening period, study participants in this group will be given a standard dose of DA-9701 (30 mg t.i.d). Concomitant anti-PD medication will be continued without modification during the trial. The investigators will evaluate dyspepsia and constipation symptoms, gastric emptying by MRI, UPDRS and clinical variables at baseline and at the end of the study.
Study NCT03022201 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Domperidone
Description: Following 2-week screening period, study participants in this group will be given a standard dose of domperidone (10 mg t.i.d). Concomitant anti-PD medication will be continued without modification during the trial. The investigators will evaluate dyspepsia and constipation symptoms, gastric emptying by MRI, UPDRS and clinical variables at baseline and at the end of the study.
Study NCT03022201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo domperidone
Study NCT03022201 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo DA-9701
Study NCT00621543 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IUD insertion [Copper T-380A or Levonorgestrel (intrauterine system) IUS]
Description: When a subject has chosen a method of intra-uterine contraception and has agreed to participate in the study, she will have the intra-uterine device of her choice inserted according to the Food and Druga Administration (FDA) instructions.
Study NCT01063101 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fucoidan (extract of Laminaria japonica)
Description: Capsule (300 mg/capsule) - oral administration - 5 different dose levels - BID
Study NCT01063101 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Cellulose filled capsule - oral administration - 5 different dose levels - BID
Study NCT02807636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered at a fixed dose of 1200 milligrams (mg) by intravenous (IV) infusion on Day 1 of each 21-day cycle until investigator-assessed disease progression per RECIST v1.1. In specific circumstances treatment may continue beyond disease progression.
Study NCT02807636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be administered at doses to achieve area under the concentration-time curve (AUC) of 4.5 milligram per milliliter into minute (mg/mL\*min) by IV infusion on Day 1 of each 21-day cycle until investigator-assessed disease progression per RECIST v1.1 or unacceptable toxicity.
Study NCT02807636 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin will be administered at doses to achieve area under the concentration-time curve (AUC) of 4.5 milligram per milliliter into minute (mg/mL\*min) by IV infusion on Day 1 of each 21-day cycle until investigator-assessed disease progression per RECIST v1.1 or unacceptable toxicity.
Study NCT02807636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine will be administered at a dose of 1000 milligrams per square meter (mg/m\^2) by IV infusion on Day 1 and Day 8 of each 21-day cycle, until investigator-assessed disease progression per RECIST v1.1 or unacceptable toxicity.
Study NCT02807636 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine will be administered at a dose of 1000 milligrams per square meter (mg/m\^2) by IV infusion on Day 1 and Day 8 of each 21-day cycle, until investigator-assessed disease progression per RECIST v1.1 or unacceptable toxicity.
Study NCT02807636 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to atezolizumab will be administered by IV infusion on Day 1 of each 21-day cycle until investigator-assessed disease progression per RECIST v1.1. In specific circumstances treatment may continue beyond disease progression.
Study NCT03448731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline 50Mg Tablet
Description: Doxycycline administered p.o once daily at a 50 mg dose for 6 weeks beginning on Day -1
Study NCT04050410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxonidine
Description: active drug given as 1 dose
Study NCT04050410 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo pill given as 1 dose
Study NCT02609607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisacodyl
Description: Rectal suppository
Study NCT02609607 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Rectal suppository
Study NCT06681961 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: squatting with hip adduction (SQU-HA) group
Description: The intervention comprised three sets of 15 repetitions with resting 5-min between sets, followed by IT band stretching for five repetitions. Each participant performed the respective exercise 5 days a week, with 2 days of rest, for 8 weeks.
Study NCT06681961 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: squatting with hip adduction (SQU-HA) group
Description: The intervention comprised three sets of 15 repetitions with resting 5-min between sets, followed by IT band stretching for five repetitions. Each participant performed the respective exercise 5 days a week, with 2 days of rest, for 8 weeks.
Study NCT06685341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YZJ-1139
Description: YZJ-1139
Study NCT06685341 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablet
Study NCT06685341 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zolpidem
Description: Oral tablet
Study NCT06683404 — intervention group
Intervention type: DEVICE
Intervention: Electrochemotherapy (ECT)
Description: Electrochemotherapy (ECT) is characterized by the association between the administration of a chemotherapic agent (Bleomycin) with the temporary raise of permeability of the cellular membrane induced by the local administration of electrical impulses (electroporation). ECT represents an effective therapy for loco-regional control of this disease.
Study NCT06683404 — intervention group
Intervention type: DRUG
Intervention: Bleomycin
Description: Electrochemotherapy (ECT) is characterized by the association between the administration of a chemotherapic agent (Bleomycin) with the temporary raise of permeability of the cellular membrane
Study NCT01048333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol
Description: Salmeterol Diskus 50 μg and Placebo Turbuhaler
Study NCT01048333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo Diskus and Placebo Turbuhaler
Study NCT03929939 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training and healthy eating (overseen by IEEM research team)
Description: Exercise Training: A personalized training program will be developed for participants. Based on maximal steady state heart rate and resting heart rate, three training zones (recovery, base pace, and maximal steady state) will be determined. The target heart rate for each training zone will be set for each patient. The majority of training sessions during the early phase of the program will be prescribed as base pace with target heart rate equivalent to about 75% of maximal. Initially, patients will train 3 times per week for 20-30 minutes per session by walking, jogging or swimming. As the patients become relatively fit, the duration of the base training sessions will be prolonged, and subsequently sessions of increased intensity (i.e., maximal steady state) will be added.~Healthy Eating: Participants will be provided with dietary advice consistent with the American Heart Association guidelines (D.A.S.H. diet eating plan).
Study NCT02883790 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Somnage
Description: Melatonin 1mg, Zinc, Magnesium
Study NCT02883790 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02472678 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Web-based tailored information and support system
Description: Access to the web-based tailored information and support system (with a username/password)
Study NCT02472678 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard care
Description: The control group will receive standard care.
Study NCT04887883 — intervention group
Intervention type: BEHAVIORAL
Intervention: Resistance exercise
Description: Participants performed 8 weeks of resistance training and muscle biopsies were taken before and 24 h before and after the program.
Study NCT00762957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-559 and metformin
Description: TAK-559 16 mg, tablets, orally, once daily and metformin stable dose orally, once daily for up to 26 weeks.
Study NCT00762957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-559 and metformin
Description: TAK-559 32 mg, tablets, orally, once daily and metformin stable dose, orally, once daily for up to 26 weeks.
Study NCT00762957 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: TAK-559 placebo-matching tablets, orally, once daily and metformin stable dose, orally, once daily for up to 26 weeks.
Study NCT04495491 — intervention group
Intervention type: OTHER
Intervention: pupillary block group
Description: According to the configurations of angle closure, the pupillary block group is defined as the iris bombe.
Study NCT04495491 — intervention group
Intervention type: OTHER
Intervention: plateau iris group
Description: According to the configurations of angle closure, the plateau iris group is defined as the thickness of the peripheral iris.
Study NCT04495491 — intervention group
Intervention type: OTHER
Intervention: mixing mechanism group
Description: According to the configurations of angle closure, the mixing mechanism group is defined as the iris bombe plus thickening of the peripheral iris.
Study NCT04126057 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SightGlass Vision DOT Spectacle Lenses
Description: Subjects randomized to test vs control, left eyes and right eyes
Study NCT04633837 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Extracellular Matrix Graft Injectable Implant
Description: The extracellular matrix injectable implant will serve as the intervention in this study.
Study NCT04450303 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth CBT
Description: The Coordinated Anxiety Learning and Management (CALM) program is an evidence-based, computer-assisted protocol for cognitive behavioral therapy (CBT) for anxiety, depression, and/or post-traumatic stress. CALM will be implemented via secure and HIPAA compliant video-conferencing software (enterprise Zoom), following modifications to address obstacles associated with physical distancing and the tele-health medium.
Study NCT03778047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: oral
Study NCT01654718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole
Description: Pantoprazole 40mg Delayed release tablets (Test Product)
Study NCT01654718 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pantoprazole
Description: Protonix® Delayed Release 40 mg tablets (Reference product)
Study NCT02401048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Study NCT03778047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HC1119
Description: oral
Study NCT02401048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736
Study NCT02907918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib is an oral drug given at a dose of 125 mg daily on Days 1-21 of each 28-day cycle for a total of 4 cycles.
Study NCT02907918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole is an oral drug given at a dose of 2.5 mg orally once a day. It will be taken continuously (Days 1-28 of each cycle) until the day of definitive surgery.
Study NCT02907918 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: * Or FDA approved biosimilar~* Trastuzumab will be administered on a weekly basis for 16 weeks (on Days 1, 8, 15, and 22 of each 28-day cycle for a total of 4 cycles). The first dose of trastuzumab on Cycle 1 Day 1 will be a loading dose of 4 mg/kg IVPB over 90 minutes. Subsequent doses of trastuzumab will be 2 mg/kg IVPB over 30 minutes. Weekly trastuzumab will continue after the completion of Cycle 4 of palbociclib until surgery.
Study NCT02907918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin
Description: Goserelin is given subcutaneously at a dose of 3.6 mg on Day 1 of each cycle. Goserelin will be continued (once every 28-days) after the completion of Cycle 4 of palbociclib if required.
Study NCT02907918 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Breast surgery
Description: Standard of care
Study NCT02907918 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Research tumor biopsy
Description: Baseline, cycle 1 day 15, and surgery
Study NCT02907918 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Research bone marrow (OPTIONAL)
Description: Baseline and surgery
Study NCT02907918 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Research blood sample
Description: Baseline, cycle 1 day 15, surgery, and yearly post-surgery for 5 years
Study NCT02807636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin will be administered at a dose of 70 mg/m\^2 by IV infusion on Day 1 of each 21-day cycle until investigator-assessed disease progression per RECIST v1.1 or unacceptable toxicity.
Study NCT02907918 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Research blood for germline DNA
Description: Baseline
Study NCT03776032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa
Description: Administered by subcutaneous injection once a week
Study NCT02907918 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood for detection of circulating tumor cells
Description: Baseline
Study NCT03776032 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to darbopoetin alfa administered by subcutaneous injection once a week.
Study NCT01829477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-875
Description: TAK-875 50 mg tablets
Study NCT01829477 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TAK-875 Placebo
Description: TAK-875 placebo-matching tablets
Study NCT01829477 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Glimepiride
Description: Glimepiride tablet.
Study NCT01829477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride
Description: Glimepiride tablet.
Study NCT00170625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hycamtin
Description: Topotecan: 1,0 mg/m²/d, day 1-3; q21d Carboplatin: AUC 5 on day 3 after Topotecan, q21d
Study NCT02389387 — intervention group
Intervention type: OTHER
Intervention: Intensive Intervention
Description: I.A multi-module, secure, web-enabled software application called Transplant Referral EXchange (T-REX):1) real-time communication between staff across healthcare settings, documenting the use of transplant education materials, 2) sending/receiving electronic referrals for transplant specific to a transplant center's requirements and 3) tracking patients' status in the transplant process (e.g., patient interest in transplant, referral for transplant, evaluation start/completion, waitlist status, and transplant) II. Educational webinars/seminars for staff, III. Facility-specific performance feedback reports, IV. Assistance with and review of center-specific action plans to increase transplant referral, V. Scheduled bi-annual phone calls with an SETC member to monitor progress, VI. Patient education on transplant via creation of an Education Station in facility lobby, VII. Development of a Peer Mentor program.
Study NCT04387019 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: blood sampling
Description: blood sampling from peripheral vein
Study NCT01019395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daptomycin
Description: Group 1: Ages 13 months to 24 months inclusive. Six subjects dosed at 6 mg/kg as a 30 minute infusion;~Group 2:Ages 7 months to 12 months inclusive: Six subjects will receive a dose of 4 mg/kg as a 30 minute infusion;~Group 3: Ages 3 months to 6 months inclusive: Six subjects will receive a dose of 4 mg/kg as a 30 minute infusion.
Study NCT02807636 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin will be administered at a dose of 70 mg/m\^2 by IV infusion on Day 1 of each 21-day cycle until investigator-assessed disease progression per RECIST v1.1 or unacceptable toxicity.
Study NCT03935776 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Risk Factors Modification Programme
Description: 12- week supervised risk factor modification programme derived from the Euroaction study standards
Study NCT03935776 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Healthcare
Description: Patients are advised to adjust lifestyle without the support of the structured supervised programme
Study NCT02919423 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial magnetic stimulation
Study NCT03262857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: use of magnesium sulfate with lidocaine in inferior alveolar nerve block
Study NCT03388749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Annamycin
Description: 2-hour intravenous infusion liposomal annamycin daily for 3 consecutive days followed by 18 days off study drug (i.e., one treatment cycle = 21 days).
Study NCT04135157 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pectoralis nerve block II
Description: PECS II block will be performed 30 min. before general anesthesia.
Study NCT04135157 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector spine plane block
Description: ESP block will be performed 30 minutes before general anesthesia.
Study NCT04135157 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Only general anesthesia will be performed.